Related Experiment Video
Updated: Jul 20, 2026

07:10
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
14.4K
Defining criteria for broadly neutralizing HIV antibodies
Elizabeth-Sharon David-Fung1, Katherine A Belobrajdic1, Jennifer P Macke1
1Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.
Frontiers in Immunology
|August 1, 2025
Summary
A small percentage of HIV-1 patients develop broadly neutralizing antibodies (bnAbs). A new tool, CAByN, helps define and identify these bnAbs from extensive neutralization data.
Area of Science:
- Immunology
- Virology
- Bioinformatics
Background:
- A subset of individuals with HIV-1 infection develop broadly neutralizing antibodies (bnAbs).
- These bnAbs are crucial for neutralizing diverse HIV-1 strains.
- Currently, a universally accepted numerical definition for bnAbs is lacking.
Purpose of the Study:
- To review key characteristics of HIV neutralizing antibodies and proposed bnAb definitions.
- To introduce CAByN, a web-based tool for identifying bnAbs based on user-defined criteria.
- To present biological insights derived from CAByN analysis.
Main Methods:
- Review of existing literature on HIV neutralizing antibodies and bnAb definitions.
- Development and utilization of the CAByN web tool.
- Analysis of data from the Los Alamos HIV Databases CATNAP database.
- Examination of antibody neutralization data across different viral clades.
Main Results:
- CAByN allows users to apply numerical definitions to identify bnAbs.
- Biological findings include differential neutralizing activity of certain antibodies against various HIV-1 clades.
- The tool aids in identifying antibodies with potentially incomplete neutralization profiles.
Conclusions:
- The CAByN tool provides a standardized approach to defining and identifying bnAbs.
- It facilitates the exploration of antibody neutralization data, revealing nuanced biological activities.
- This resource can advance research in HIV vaccine development and antibody-based therapies.

